Product Pipeline
We are driven to develop innovative and novel medicines to help address unmet medical needs and to elevate life through science.
Our pipeline information may include a reference to an investigational agent or an investigational use of the FDA approved product. Safety and efficacy for investigational uses or agents have not been established or approved by the FDA. This table provides an overview of selected projects in development and can be filtered by both therapeutic area and development phase.
NUPLAZID ® (pimavanserin) was approved by the FDA in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Click for Important Safety Information, including Boxed WARNING.
DAYBUE™ (trofinetide) was approved by the U.S. Food and Drug Administration (FDA) in 2023 for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. Click for Important Safety Information.
Acadia recently completed a meeting with the FDA and plans to initiate a Phase 3 study in the fourth quarter of 2023.
Phase 1 evaluation enabling future studies in patient populations is complete. Acadia has met with FDA to discuss the clinical development plan.
Acadia secured exclusive worldwide rights to ACP-2591 in both Rett syndrome and Fragile X syndrome.
Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.